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Abstract The purpose of the present study was to investigate
systemic and local levels of platelet-activating factor (PAF), a
potentproinflammatorymediatorimplicatedincardiovascular
pathophysiology in adult nonsmoking patients with perio-
dontitis with or without coronary heart disease (CHD).
Eighty-seven volunteers, 25 periodontitis patients, 19 perio-
dontitis with CHD patients, 19 CHD patients, and 24 healthy
controls were included, and periodontal conditions were
assessed. Gingival crevicular fluid (GCF) and venous blood
were collected, and PAF levels were measured by enzyme-
linked immunosorbent assay. PAF levels in serum (303.3±
204 pg/ml) and in GCF (26.3±6 pg/μl) of the periodontitis
group with CHD, the periodontitis group (serum, 302.4±
241 pg/ml and GCF, 26.3±8 pg/μl) and the CHD group
(serum, 284.7±192 pg/ml and GCF, 20.8±6 pg/μl) were
significantly higher than the healthy control group (serum,
65.4±35pg/ml and GCF, 7.7±3 pg/μl;p<0.05).Insummary,
the present study could demonstrate that in patients with
periodontitis, the inflammatory mediator PAF is released into
serum at least in the same range as for patients with coronary
heart disease. However, no additive effects were seen when
both conditions were present.
Keywords Oralinflammation.Systemiceffects.Platelet-
activatingfactor.Periodontitis.Coronaryheartdisease
Introduction
A series of genetic and environmental risk factors such as
hypertension, hypercholesterolemia, dyslipidemia, obesity,
diabetes mellitus, and smoking are well-established risk
factors for atherosclerotic cardiovascular diseases [1].
During the past 15 years, the hypothesis was raised that
chronic infections may contribute to the development of
atherosclerosis [2, 3]. Published data have also shown that
oral inflammation and periodontal disease in particular
could increase the risk for coronary heart disease (CHD)
[4–7]. However, the pathways by which inflammatory
processes may contribute to cardiovascular disease are still
unclear [8].
Platelet-activating factor (PAF) is one of the most potent
and versatile proinflammatory mediators found in mammals
[9]. It can be produced and released from a variety of cells,
especially activated inflammatory cells such as macro-
phages, thrombocytes, and lymphocytes [10]. PAF pro-
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DOI 10.1007/s00784-009-0346-5motes the aggregation, chemotaxis, granule secretion, and
oxygen radical generation from leukocytes and the adher-
ence of leukocytes to endothelium [11, 12]. PAF increases
the permeability of endothelial cell monolayers and
stimulates the contraction of smooth muscle [10]. These
physiological activities of PAF support the hypothesis that
PAF may play a role in the initiation and progression of
CHD [13–15]. Clinical animal studies have shown higher
levels of PAF in coronary artery samples from animals with
severe atherosclerosis compared to healthy controls [16].
Since the presence of PAF in human mixed saliva was
first reported, only a few studies have tried to reveal the
relationship between PAF and periodontal inflammation
[17, 18]. It has been demonstrated that PAF released by
inflamed periodontal tissues could be measured within the
gingival sulcus fluid [18] and was reduced after periodontal
therapy [19]. In a previous study of our group, a significant
positive correlation was observed between periodontal
parameters and the levels of PAF in both serum and
gingival crevicular fluid (GCF) from patients suffering from
periodontitis [20]. The detection of this metabolite in blood
from patients suffering from periodontitis is a precondition
for a possible molecular link between the lipid mediator
PAF originating from inflamed periodontal tissues and the
development of CHD.
We have previously shown that periodontitis is associ-
ated with elevated systemic levels of the inflammatory
mediator PAF, which is implicated in the pathopysiology of
coronary heart disease and hypothesize that additive or
synergistic effects on PAF serum levels might be found if
both conditions are present. Therefore, the purpose of the
present study was to investigate local and systemic PAF
levels in adult patients with periodontitis, with our without
concomitant coronary heart disease in comparison to
healthy individuals.
Methods
Study population
A total of 87 nonsmoking subjects were recruited from the
School of Medicine, Zhejiang University, China into the
study (Table 1). Thirty-eight patients with proven CHD
were treated between December 1999 and June 2005. All
patients with CHD had suffered from a recent history of
severe angina pectoris symptoms (less than 6 months prior
to the study) as verified by hospitalization and a significant
diameter stenosis of at least 50% in one or more coronary
arteries, diagnosed by coronary angiography. In addition, a
group of 49 subjects, presenting with or without perio-
dontitis, participated in this study. Informed consent was
obtained from all patients, and the study was approved by
the Ethics Committee of Zhejiang University. The same
examiner conducted all periodontal assessments.
All subjects were classified into four groups:
Periodontitis group (Perio) Twenty-five subjects (13
females, 12 males; age, 23–52 years) with proven perio-
dontitis. Patients were classified based on the clinical
examination including periodontal probing depth ≥4 mm,
bleeding on probing, and an attachment loss ≥2m mo fa t
least four teeth, as well as radiographic evidence of bone
loss.
Coronary heart disease group (CHD) Nineteen subjects
(seven females, 12 males; age, 38–50 years) with proven
CHD, but no signs of attachment loss observed from
clinical and radiographic examination. No evidence of
diabetes mellitus, stroke, or other severe systemic diseases
was found in these patients.
Periodontitis and CHD group (Perio + CHD) Nineteen
subjects (six females, 13 males; age, 45–55 years) with
proven CHD and periodontitis according the criteria for
groups Perio and CHD.
Healthy control (Control) Twenty-four subjects (14
females, 10 males; age, 22–53 years) with no clinical or
radiographic evidence of periodontal or systemic diseases.
In the groups Perio and Control, no participant had a
history of systemic diseases according to their self-reported
medical history, received antibiotics or other medication, or
periodontal treatment within the past 4 weeks.
Clinical examination
All subjects underwent a comprehensive clinical periodon-
tal examination. At six sites of each existing tooth probing
depth (PD), clinical attachment level (CAL), bleeding on
Table 1 Age and gender of the investigated groups
Group Gender Number Age (years)
Mean SD
Perio + CHD male 13 48.50 3.20
female 6 48.00 2.50
Perio male 12 39.20 5.30
female 13 40.50 8.50
CHD male 12 44.90 3.80
female 7 42.40 2.30
Healthy male 10 32.90 6.40
female 14 38.70 7.50
630 Clin Oral Invest (2010) 14:629–636probing (BOP), sulfide levels (SUL), and plaque index
(PLI) were recorded. BOP was recorded 20 s after gentle
probing. Sulfide levels were measured using the Diamond
Probe/Perio 2000 system (Diamond General Development
Corp., USA). The system is a dental device designed to
detect sulfide concentrations of various forms (S, HS, H2S,
and CH3SH) within the gingival sulcus [21] and combines a
conventional Michigan “O” style dental probe with a
sulfide sensor. Radiographs were obtained to determine
any radiographic bone loss.
Sampling of GCF and serum
GCF samples were collected with filter paper as previously
described [22]. For the groups Perio and Perio + CHD, the
GCF samples were collected from the four deepest sites in
each quadrant. For the groups CHD and Control, the GCF
samples were collected from the mesiobuccal surfaces of the
first molar in each quadrant. If the first molar was absent, the
second molar was sampled. Prior to GCF sampling, the tooth
surfaces were dried gently by an air syringe and were
isolated by cotton rolls. Supragingival plaque was gently
removed. Paper strips were carefully inserted into the crevice
until mild resistance was felt and were left in place for 30 s.
Care was taken to avoid mechanical injury. Strips contam-
inated with blood were discarded. Papers were weighed
before and after sampling to calculate the mass of the GCF
sample. The strips were separately placed into a 1.5 ml
Eppendorf tube and kept at −20 C° until analysis.
At the same time 3 ml venous blood was sampled from
the cubital vein of each subject. The whole blood samples
were centrifuged (2,000 ppm for 2 min), and serum was
stored at −70 C° in Eppendorf tubes until future processing.
Laboratory assays
The quantitative measurement of PAF in serum and GCF was
performed using an enzyme-linked immunosorbent assay
(Human Serum PAF Assay Kit, TPI Inc., USA). Each GCF
sample was analyzed separately by soaking the filter paper in
1 ml diluent solution to elute PAF. All procedures were
performed according to the manufacturer’s instructions, and
GCF and serum samples were assayed in duplicate.
Statistical analysis
For all parameters, means and standard deviations were
calculated using the individual subject as the statistical unit.
Differences between the four investigated groups with respect
totheperiodontalparametersandPAFlevelsinGCFandserum
were tested for statistical significance using the Kruskal–Wallis
Test. In case of a significant difference, a 2-group comparison
was conducted using a post hoc test. A value of p<0.05 was
considered as statistically significant. To analyze the correla-
tions between PAF levels and periodontal parameters, the
patients were the statistical unit, and Spearman rank correla-
tion analysis was performed. All statistical analyses were
performed using the SAS statistical software package.
Results
Periodontal parameters
The mean values for the clinical parameters in each group are
presented in Table 2. For all periodontal parameters, no
significant differences were found between the Perio + CHD
and the Perio groups. The mean values for PD and CAL in
the Perio + CHD and the Perio group were significantly
higher than the values in the CHD group and the healthy
control group (p<0.001). The mean PD in the CHD group
was slightly higher compared to the healthy controls.
The bleeding scores in Perio + CHD group were
significantly higher than the scores in the CHD group (p=
0.006) and the healthy control group (p<0.001). BOP in the
Perio group was significantly different compared to the BOP
scores of the CHD group (p=0.001) and the control group
(p<0.001). Statistically significant differences were also
observed for BOP between the CHD group and the healthy
control group (p<0.001).
Table 2 Mean values and standard deviation for oral clinical parameters of the investigated groups
Group Number PD (mm) CAL (mm) BOP (%) PLI SUL (%)
Mean SD Mean SD Mean SD Mean SD Mean SD
Perio+CHD 19 4.82 0.57
a,b 5.68 1.89
a,b 62.95 16.10
a,b 2.75 0.18
a 26.99 8.30
a
Perio 25 4.61 0.80
a,b 5.98 1.29
a,b 59.78 19.41
a,b 2.76 0.17
a 28.03 8.44
a
CHD 19 2.52 0.46 0.00 0.00 42.65 18.89
a 2.61 0.38
a 21.72 8.00
a
Healthy 24 2.16 0.26 0.00 0.00 7.09 6.70 1.42 0.68 5.98 5.50
aStatistically significant difference to the healthy controls (Kruskal–Wallis Test followed by post hoc test (p<0.05)
bStatistically significant difference to group CHD (Kruskal–Wallis test followed by post hoc test; p<0.05)
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from the PLI in the healthy control group (p<0.001). No
statistically significant differences were observed between
the PLI scores of Perio + CHD group, Perio group, and
CHD group (p=0.589).
All patient groups showed significantly higher SUL
levels than the healthy controls (p<0.001). No significant
difference was observed of SUL levels between Perio +
CHD and CHD groups (p=0.283) or between Perio and
CHD group (p=0.090).
PAF levels in serum
The levels of PAF in GCF and serum of the four groups
under investigation are shown in Table 3. The data show
significant differences of serum PAF levels between Perio +
CHD, Perio, and CHD groups compared to the healthy
controls (p<0.001). No significant differences were ob-
served between the three patient groups.
PAF levels in GCF
Values for the total amount of PAF per sample (pg/sample)
andforthePAFconcentration(pg/μl)arepresentedinTable3.
All patient groups showed significantly higher PAF levels in
GCF on a per sample and on a concentration basis compared
to the Control group (p<0.001). No significant differences of
PAF levels in GCF were calculated between Perio + CHD
and Perio group. The PAF levels in GCF for Perio + CHD
group and Perio group were significantly higher (p=0.002
and p<0.001, respectively) compared to CHD group. On a
concentration basis, the PAF levels in the GCF of Perio +
CHD group were significantly different from the PAF levels
of the CHD group (p=0.039). No significant difference
between Perio and CHD group were observed (p=0.051).
PAF levels in GCF compared to serum
The results of the Spearman correlation analysis are
presented in Fig. 1. A significant positive correlation was
observed for all three patients groups for the PAF
concentration in serum and the total amount of PAF in
GCF (r=0.748, p<0.001) and for the concentration of PAF
in GCF (r=0.784, p<0.001). For the CHD group, the PAF
levels in serum (pg/ml) and in GCF (pg/μl and pg/sample),
a significant positive correlation was found (r=0.927, p<
0.001 and r=0.883, p<0.001, respectively), as well as for
the Perio group (r=0.807, p<0.001 and r=0.787, p<0.001,
respectively) and for the Perio + CHD group (r=0.930, p<
0.001 and r=0.880, p<0.001, respectively). In healthy
individuals, the PAF levels in serum and GCF showed only
low correlations (r=0.558, p<0.001 and r=0.452, p=0.005,
respectively).
Periodontal parameters compared to PAF levels
For the Perio group, a significant correlation between the
periodontal parameter PD and the PAF levels in serum (r=
0.732, p<0.001) and GCF (r=0.792, p<0.001) was ob-
served. For the parameter BOP, a correlation with serum PAF
levels of r=0.609 (p<0.001) and with GCF PAF levels (pg/
sample) of r=0.488 (p=0.001) was calculated. For the CHD
group, a significant correlation between PD and serum PAF
levels (r=0.692, p<0.001) or GCF PAF levels (r=0.752, p<
0.001) was observed. For the parameter BOP, a correlation
with serum PAF levels of r=0.836 (p<0.001) and with GCF
PAF levels (pg/sample) of r=0.743(p=0.001) was calculated
for this group. For the patients suffering from periodontitis
and coronary heart disease (Perio + CHD group), a
significant positive correlation was observed between the
serum PAF levels (pg/ml) and the clinical parameter PD (r=
0.845, p<0.001), CAL (r=0.751, p<0.001), and PLI (r=
0.840, p<0.001). These patients also showed a significant
correlation between the GCF PAF levels (pg/sample) and the
clinical parameter PD (r=0.0.798, p<0.001),CAL(r=0.751,
p<0.001), and PLI (r=0.803, p<0.001). The Perio + CHD
group showed, for the parameter BOP, a correlation with
serum PAF levels of r=0.563 (p=0.001) and with GCF PAF
levels (pg/sample) of r=0.540 (p=0.001). In healthy sub-
jects, all clinical periodontal parameters showed low corre-
lations with the PAF levels in serum (pg/ml) and in GCF (pg/
sample; data not presented).
Table 3 Mean values of PAF in GCF and serum for the investigated patient groups and healthy controls
Perio+CHD Perio CHD Healthy
Mean SD Mean SD Mean SD Mean SD
PAF in serum (pg/ml) 303.33 204.92
a 302.37 240.58
a 284.71
a 192.40
a 65.38 34.85
PAF in (pg/sample) 21.41 6.50
a,b 21.35 5.87
a,b 14.59 3.14
a 2.96 2.80
PAF in GCF (pg/μl) 26.33 6.11
a,b 26.31 7.49
a 20.83 5.63
a 7.66 3.52
aStatistically significant difference to the healthy controls (Kruskal–Wallis Test followed by post hoc test; p<0.05)
bStatistically significant difference to group CHD (Kruskal–Wallis Test followed by post hoc test; p<0.05)
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Atherosclerosis, with its major manifestation of coronary
artery disease, remains a major cause of mortality in
western populations, and epidemiological studies have
identified several risk factors such as smoking, diabetes
mellitus, hypertension, and dyslipidemia in the etiology of
atherosclerosis [1]. Recently, studies have indicated that
periodontitis may lead to alterations in systemic health [23]
and may influence the occurrence and the severity of
coronary artery disease [24–26]. However, whether peri-
odontal infections play a causal role in the occurrence of
coronary artery disease is still debated [27].
Two hypothetical pathways could be considered for the
systemic effects of periodontal infections. One hypothesis is
that periodontal pathogens could enter the bloodstream and
have atherogenic effects. The direct invasion of blood
vessel and atherosclerotic plaques by periodontal pathogens
has been described [28]. In fact, recently, a broad variety of
molecular signatures from a diverse bacterial colonization
Fig. 1 Correlation analysis between the PAF levels in serum (pg/ml) and GCF (pg/sample; pg/ul) for a all patients groups, b the Perio group, c
Perio + CHD group, and d the CHD group
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Another hypothesis raised by several studies is based on
elevated levels of inflammatory mediators circulating in the
bloodstream. Cross-sectional and prospective studies have
established that elevated peripheral blood levels of several
systemic inflammatory markers including C-reactive pro-
tein, fibrinogen, PAF, and the cytokines IL-1ß and IL-6 and
TNF-alpha are associated with the risk of cardiovascular
diseases and the severity of atherosclerosis [15, 30–33]. It
has been proposed that these mediators are elevated during
periodontal infection and their proinflammatory properties
may subsequently increase the existing inflammatory
activity in plaque-associated lesions in coronary arteries.
Therefore, a systemic elevation of the concentration of an
inflammatory mediator like PAF released from
periodontitis-affected tissues could explain at least in part
the observed association of periodontitis with cardiovascu-
lar disease.
As a potent phospholipid mediator of inflammatory and
immune reactions, PAF contributes to numerous pathologic
reactions in vivo. PAF activates neutrophils and causes
chemotaxis aggregation, superoxide generation, and de-
granulation. PAF synthesized by endothelial cells and
exposed on the cell surface may, together with P selectin,
promote leukocyte adhesion to endothelial cells [34]. This
interaction may be important for the activation and the
subsequent infiltration of monocytes–macrophages, the
production of proliferative cytokines, and accumulation of
lipids within the cells and in consequence, for the biological
role of PAF in atherosclerosis [13, 35]. The role of PAF in
ischemia and reperfusion injury of the heart is supported by
clinical experiments [36]. Moreover, cigarette smoking
associated with the pathogenesis of atherosclerosis causes
platelet activation, LDL oxidative changes, and increased
levels of PAF [37].
In the present study, PAF levels in serum and gingival
crevicular fluid from patients with periodontitis, periodon-
titis and coronary heart disease, and coronary heart diseases
were compared to healthy subjects. To our knowledge, this
is the first report of PAF levels in serum and GCF from
these distinct patients groups and healthy controls. The
interpretation of the results is limited by the fact that
information of systemic and general health characteristics is
not completely available for the present study population
and in consequence, other traditional risk factors for
cardiovascular diseases were not included in the analysis.
However, all participants were nonsmokers, and smoking is
a well-established risk factor for cardiovascular diseases
[1]. It would be, of course, of interest to know all other
kinds of infections or inflammatory processes of the
participants that may increase serum PAF levels. For
patients suffering from periodontitis or CHD, elevated
levels of PAF were found in serum in comparison to
healthy controls; however, the concurrent diagnosis of
periodontitis and CHD did not show significant changes
in the systemic levels of PAF. In a study of glomerulone-
phritis, whole blood PAF levels in healthy individuals of
approximately 0.5 pg/ml and 1.0 pg/ml for patients
suffering from glomerulonephritis have been reported
[38]. However, comparison of these values is limited by
different analyzing methods and the detection in whole
blood or in serum.
It is interesting to see that the PAF levels from patients
with periodontitis, patients with periodontitis and CHD, and
patients exclusively with CHD did not show significant
differences of the serum PAF levels. A similar observation
was also documented in two studies measuring C-reactive
protein (CRP) in patients with periodontitis and patients
who developed cardiovascular events [39, 40]. For patients
with generalized periodontitis, a median value for CRP of
1.90 mg/L was reported, which was in a similar range
measured for men who developed cardiovascular events
with median baseline CRP levels of 1.26 to 1.51 mg/l.
These data are in agreement with the results of the present
study demonstrating similar systemic levels of inflammato-
ry mediators irrespective of the origin of the tissues
involved in the inflammatory process. However, the
underlying systemic regulatory mechanisms for the de-
scribed observations are not clear. PAF released from
atherosclerotic plaques or periodontal tissues into venous
capillaries is exposed to several regulatory mechanisms,
and biochemical processes during passage of the arterial
system and capillary tissues before it reaches the venous
system of the arm where the sample is collected. For
example, a key mechanism for the removal of PAF in blood
is hydrolysis catalyzed by PAF acetylhydrolase (PAF-AH),
which converts PAF to the biologically inactive lyso-PAF
[41]. The removal from the circulation by degradation, as
well as the local production of PAF by inflammatory cells
in the inflamed periodontal and gingival tissues can explain
the observed differences of PAF concentrations in GCF
compared to serum.
When measuring the inflammatory mediator PAF in
GCF proximal to the inflammatory reaction of the peri-
odontal tissues, the PAF levels in GCF were found to be
significantly elevated for patients suffering from periodon-
titis and patients suffering from periodontitis and CHD
compared to patients with CHD. In contrast to serum levels,
this observation showed the additional effect of the
systemic levels and the local PAF levels in GCF from
periodontitis. This observation was found on per sample
base, but not for concentrations. However, the expression of
metabolites in GCF as a total amount per standardized
sampling time is a more sensitive way than reporting them
as concentrations [42]. In a study of Turkish patients
suffering from chronic periodontitis, PAF levels of
634 Clin Oral Invest (2010) 14:629–636194.11pg/μlinGCFandfromhealthyindividuals,PAFlevels
of approximately 15 pg/μl were measured after HPLC
extraction and radioimmunoassay-based quantification [18].
In a study initiated to study the PAF concentration in GCF
by HPLC, approximately 470 ng/ml PAF was found in the
GCF before periodontal treatment, which was in contrast to
the 56 ng/ml PAF found 24 weeks after periodontal therapy
[43]. The observed differences between these studies may
originate from different sampling and analyzing methods. In
addition, it has been shown that initial periodontal therapy
(home care instruction, prophylaxis, and scaling/root plan-
ing) can reduce salivary PAF levels in concert with
improvements in clinical parameters of periodontal inflam-
mation [44]. Salivary PAF most likely originates from the
crevicular space and derives from inflammatory cells within
the gingival and/or periodontal tissues [45].
In conclusion, these data and the correlation analysis
between GCF and serum levels verified that PAF is released
from periodontitis affected tissues into GCF and contributes
to increased serum levels of the mediator measured in
periodontitis patients.
The PAF levels in both serum and GCF of all patients
had significantly positive correlations with all periodontal
parameters and they increased with the severity of the
periodontal inflammation and destruction. These observa-
tions showed that the elevated PAF levels in GCF and
serum were from the inflammatory process of the peri-
odontal tissues and that this mediator plays a pivotal role in
the inflammatory process of the periodontal tissues. The
results confirmed recently published data for patients
suffering from periodontitis [20]. Surprisingly, the clinical
inflammatory marker BOP was less correlated with the PAF
levels in serum from patients suffering from periodontitis
than from patients with CHD. Although, CHD patients
showed PD levels in the range of the healthy controls, they
demonstrated increased plaque levels resulting in increased
bleeding tendency indicating that the CHD patients suffered
from gingivitis. The slightly higher probing depths were
most likely due to gingival swelling. It could be speculated
that the elevated levels of PAF in serum and GCF resulted
from the inflammatory processes of the endothelium, and
may have decreased the antibacterial immune response of
the gingival tissues following increased accumulation of
plaque. Reduced oral hygiene could also be a factor
associated with a low socioeconomic status of the patients,
which is a risk factor for coronary heart diseases [46]. In
our previous work [20], in different patients, we could
establish serum and GCF PAF levels in patients with
periodontitis, gingivitis, and in healthy controls. All values
for the periodontitis group and the healthy controls were
very similar to our present findings and could, thus, be
confirmed. In contrast, the gingivitis group in the previous
study demonstrated similar GCF values but lower serum
PAF levels (138±77 pg/ml) compared to the CHD group
(284±192 pg/ml) in the present study. We interpret these
data—derived from a “historical” control group—as an
indication that at least part of the elevated serum PAF in the
patients with CHD has to be attributed to their systemic
condition. Unfortunately, for the present study, it was not
possible to recruit CHD patients without any signs of
gingival inflammation. Therefore, the relative contribution
of CHD and gingivitis on elevated serum PAF levels could
not be determined more precisely.
Taken together, our data provide evidence that the
inflammatory mediator PAF is released from periodontitis-
affected tissues into serum at least in the same range as the
PAF levels measured for patients with coronary heart
disease. However, no additive effects were seen when both
conditions were present.
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